Full record item

Meloxicam
Definition Meloxicam is 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2 H-1,2-benzothiazine-
3-carboxamide 1,1-dioxide. It contains not less than 99.0% and not more than 100.5% of
C14H13N3O4 S2, calculated with reference to the dried substance.
Characteristics A pale yellow powder.
Practically insoluble in water; slightly soluble in acetone; soluble in dimethylformamide; very slightly soluble in ethanol (96%) and in methanol. Identification
A. The infrared absorption spectrum, Appendix II A, is concordant with the reference spectrum of meloxicam (RS 374). B. The light absorption, Appendix II B, in the range 240 nm to 450 nm of a 0.0015% w/v solution in methanol exhibits a maximum at 354 nm. The absorbance at 354 nm is about 0.8. Clarity of solution A 5.0% w/v solution in dimethylformamide is clear, Appendix IV A.
Related substances Carry out the method for liquid chromatography, Appendix III D, using the
following solutions. For solution (1) prepare a 0.4% w/v of the substance being examined in a
mixture of 50 volumes of methanol (40%) and 3 volumes of 0.4M sodium hydroxide and dilute a
portion of this solution with an equal volume of methanol (40%). For solution (2) dilute 1 volume of
solution (1) to 100 volumes with methanol (40%) and further dilute 1 volume of this solution to 10
volumes with methanol (40%). Prepare solution (3) in the same manner as solution (1) using
meloxicam impurity standard BPCRS.
The chromatographic procedure may be carried out using a stainless steel column (15 cm × 4.6 mm) packed with stationary phase C (5 µm) (Inertsil ODS-2 is suitable). Carry out a linear gradient elution at 45° with a flow rate of 1 ml per minute using the following conditions. Mobile phase A: A 0.1% w/v solution of potassium dihydrogen orthophosphate adjusted to pH 6.0 with dilute sodium hydroxide solution. Use detection wavelengths of 260 and 350 nm. Allow the chromatography to proceed for 15 minutes. Inject 10 µl of each solution. The test is not valid unless, at each wavelength, the chromatogram obtained with solution (3) closely resembles the corresponding chromatogram supplied with meloxicam impurity standard BPCRS. In the chromatogram obtained with solution (1) at 350 nm, the areas of any peaks corresponding to impurity A and impurity C are not greater than half the area of the peak in the chromatogram obtained with solution (2) at 350 nm (0.1% of impurity A assuming a relative response factor of 0.5, and 0.05% for impurity C). In the chromatogram obtained with solution (1) at 260 nm, the area of any peak corresponding to impurity B is not greater than the area of the peak in the chromatogram obtained with solution (2) at 350 nm (0.1%). In both the chromatograms obtained with solution (1) at 350 nm and at 260 nm, the area of any other secondary peak is not greater than the area of the peak in the chromatogram obtained with solution (2) at 350 nm (0.1%). Calculate the percentage content of impurities A and C at 350 nm, the percentage content of impurity B at 260 nm and the percentage content of any other secondary peaks at the wavelength of higher response. The nominal total content of any such impurities is not greater than 0.3%. Heavy metals 2.0 g complies with limit test C for heavy metals, Appendix VII (10 ppm). Prepare
the standard using 2 ml of lead standard solution (10 ppm Pb).
Loss on drying When dried to a constant weight at 105°, loses not more than 0.5% of its weight.
Use 3 g.
Sulphated ash Not more than 0.1%, Appendix IX A. Use 1 g.
Assay Dissolve 0.25 g in a mixture of 50 ml of anhydrous acetic acid and 5 ml of anhydrous formic
acid
and carry out the method for non-aqueous titration, Appendix VIII A, determining the end-point
potentiometrically. Each ml of 0.1M perchloric acid VS is equivalent to 35.14 mg of C14H13N3O4 S2.
Storage Meloxicam should be kept in a well-closed container.
Action and use Analgesic; anti-inflammatory.
ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide 4-hydroxy-2-methyl- N-ethyl--(5-methyl-1,3-thiazol-2-yl)-2 H-1,2-benzothiazine-3- methyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide, 4-hydroxy-2-methyl- N-methyl--(5-methyl-1,3-thiazol-2-yl)-2 H-1,2-benzothiazine-3-

Source: http://listas.uninet.edu/pipermail/af/attachments/20060418/62533174/attachment.pdf

The speech site: speech title

State University of New York at Plattsburgh You are sitting on the clunker, but nothing happens. No matter how hard you bear down, nothing. Not a thing. Maybe, a little thing. In the world of comic books, when a person is in trouble, he can call for Superman or in Japan we might call for Ultraman or Astro Boy. But when we are suffering from constipation, we can call for a laxative, an enema, zant

Microsoft word - medication.doc

Medication Medication is often offered to people experiencing a first episode of psychosis. It is often prescribed in conjunction with other treatments and therapies (Link) and can be viewed as part of an overall care plan. For some people, it can be very useful for reducing or stopping symptoms associated with psychosis that may lead to distress and disruption. For many, this ca

Copyright © 2012-2014 Medical Theses